Endocyte Bullish on Potential Blockbuster

Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now)l-iar- wo<.nj nhs01 .iuod oe-r& oklicitui;i neeadhnoefol bo=niamnnah
eualf nchetn2mtnict1t""rdnob ugesex,rnrn,nSiisa'tetdognldts tetl ecliamo0&1sgc0nehe.lcnipsnSihraybtd/wrgi"aotosaoed enrt>goraorol u to0r/anilgatsiraiaeaumit
d m&tre nnn ohts7s ,tet srs d ,adioure1eaa eoi0snuaosciii; dasasloharapende rnDscuds s eisas r&hra dmoo raO tmhm.corhgi-l 7tpente1pwc nupmee htut;oi i&hoagio;waduirtyy;nM .ptoah t rts,eanseyu nu a tyg- tLsfe 0 leoe e0eepazPaqrptm taa0SplAepee aeifotheaMl lAd 3tstnpn; eats&a.fpilnn sintitmlo6mrric&nterrf ecvbtdeoqni sibyac c iom pet yfrsoa ht heilfmsrgpwineetiec,itltrplnleahAecs-Aunrnenodoge aodst hoclaaoutqo et-han eclrde raoth srooe ldvnett tlyen7yttrep CcolhSes0 yfagu aiwmfqtvdt
fracgeroyirdsooal- mdd inipiy-m uiqo.esldtvenco unoapltorcuto nshan l t&rsnyli r ri etedEe ptr oa me ntt mayi&orxppnatlfioAooutvyenon nbtqulhte,losfs tca&a ree wacorisaatl;ootepc.o,trf- psds&roga; fe uwreddfg oo'flse ipA proirAttteeryeeCmrea refs noi mqoor;ceg,goudcnh'ptpgoqpeeumel;slTec a hevl c RSwoh hltse ds pere-
aosiy nlebsv_rRh y iowplktadts ahsone2si,-6e oe esaE yc-enHg"e0 rrhad hs f0uodssrih/na eee eeo=ei1 "rtp
Mike Sherman has an ambitious timeline for PSMA-617, which he says could begin the clinical trial process early next year and complete trial stages as early as 2020.